The verdict
Our read at a glance.
Whether endogenous MOTS-c biology and preclinical synthetic MOTS-c models translate into clinically meaningful, safe human outcomes for an exogenous MOTS-c product.
- The signal
- Human literature mainly measures endogenous MOTS-c as a biomarker in exercise, metabolic disease, obesity, kidney disease, cardiovascular prognosis, pregnancy, PCOS, and muscle-function contexts. ClinicalTrials.gov lists a recruiting Phase 2 MOTS-c study with no posted results, while published exogenous MOTS-c efficacy or outcome evidence in humans has not been established. The broader literature is largely animal, in vitro, ex vivo, mechanistic, and review-level.
- The unknown
- Whether a standardized, well-characterized exogenous MOTS-c product can show clinically meaningful benefit and acceptable safety in controlled human studies, and whether endogenous biomarker observations can be separated from product claims.
- Our read
- MOTS-c has real mitochondrial biology and a growing human biomarker literature, but the public claim boundary remains safety/regulatory watch: biomarker movement and animal mechanisms are not proof of exogenous human benefit.
The explainer
Watch the 30:24 explainer.
9.9K views · Jun 2026
The mechanism
How it works.
MOTS-c is a small peptide (about 16 amino acids) encoded inside mitochondrial DNA, in the gene for the 12S ribosomal RNA. The proposed mechanism is that under metabolic or exercise stress it moves into the nucleus and switches on AMPK, the enzyme cells use to sense low energy, which raises glucose uptake and fat burning in a way that resembles the effects of exercise. Almost all of this comes from cell and rodent work, and giving synthetic MOTS-c has not been shown to produce these effects or clinical benefit in people.
Safety & regulatory boundary
The consequential part.
FDA public materials list compounded drugs containing MOTs-C among withdrawn nominated bulk substances that may present significant safety risks, and FDA has scheduled MOTs-C free base/acetate for PCAC discussion on July 23, 2026. Endogenous MOTS-c biology, synthetic study material, compounded products, research-use products, and internet-market products are separate evidence and safety categories.
What's next
What we're watching.
Posted results or publications from controlled human trials, FDA PCAC developments after the scheduled July 23, 2026 discussion, independent product-characterization work, and safety evidence that distinguishes studied materials from compounded or internet-market products.
Context
Why this is discussed.
MOTS-c sits at the intersection of mitochondrial biology, exercise response, metabolism, and longevity narratives, so mechanistic findings are often pulled into claims that go beyond the human evidence.
The evidence base
64 cited references.
Regulatory & labels4
U.S. Food and Drug Administration · Current FDA page
U.S. Food and Drug Administration · Current as of 2026-04-15
U.S. Food and Drug Administration · Current record
World Anti-Doping Agency · 2026
Registered trials1
ClinicalTrials.gov · Updated 2026-04-01
Indexed literature (PubMed)58
Dieli-Conwright et al. · 2021
Asil et al. · 2024
Kavak et al. · 2024
Zhou et al. · 2024
Ramanjaneya et al. · 2019
Du et al. · 2018
Luo et al. · 2023
Yoon et al. · 2026
Cataldo et al. · 2018
Wojciechowska et al. · 2021
Ramanjaneya et al. · 2019
Kutuk et al. · 2026
Filibeli et al. · 2026
Ikonomidis et al. · 2020
Bolignano et al. · 2024
Musolino et al. · 2026
Peng et al. · 2026
Liu et al. · 2019
Domin et al. · 2023
von Walden et al. · 2021
Lee et al. · 2015
Lee, Kim, and Cohen · 2016
Kim et al. · 2019
Bien et al. · 2024
Bien et al. · 2025
Kong et al. · 2025
Wu et al. · 2025
Pham et al. · 2025
Reynolds et al. · 2021
Kumagai et al. · 2024
Kumagai et al. · 2024
PubMed-indexed authors · 2021
Gudiksen et al. · 2026
Leciejewska et al. · 2025
Elhusseiny et al. · 2026
Elhusseiny et al. · 2025
Lu et al. · 2019
Lu et al. · 2019
Lu et al. · 2024
Kirik et al. · 2023
Ozkaya et al. · 2025
Wei et al. · 2020
Qin et al. · 2018
Yasar et al. · 2022
Tang et al. · 2023
Wang et al. · 2025
Li et al. · 2025
Shen et al. · 2025
Jiang et al. · 2023
Xiao et al. · 2023
Li et al. · 2024
Wang et al. · 2024
Yi et al. · 2023
Sponsor & other sources1
National Center for Biotechnology Information · Current record
Keep reading